Payment overview · 2025
General Payments
$5,046.96
186 reported records · 24 companies
Healthcare provider profile · identity verified
Hormoz Kianfar, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · BRICK, NJ · NPI 1306008727
Verified facts
What the public records show
CMS Open Payments records show Hormoz Kianfar, MD received $5,046.96 in general payments during 2025 across 186 reported records.
Medtronic, Inc. accounted for 57.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Farxiga, Jardiance, Ozempic, Rybelsus, Wegovy.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 511 claims for Eliquis by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Nexlizet by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 511 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$2,901.06 | 57.5% | 34 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $319.95 | 6.3% | 23 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $283.34 | 5.6% | 22 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $238.61 | 4.7% | 15 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $230.12 | 4.6% | 19 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $218.81 | 4.3% | 17 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $159.97 | 3.2% | 22 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $98.59 | 1.9% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $92.59 | 1.8% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $87.05 | 1.7% | 5 | 2025 |
| Impulse Dynamics (USA) Inc. | Unresolved — no canonical attribution shown | $78.29 | 1.6% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $48.55 | 1.0% | 3 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $46.78 | 0.9% | 2 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $37.33 | 0.7% | 2 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $34.36 | 0.7% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $31.94 | 0.6% | 2 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $23.92 | 0.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.87 | 0.4% | 1 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $18.54 | 0.4% | 1 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $16.72 | 0.3% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.81 | 0.3% | 1 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $14.71 | 0.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.62 | 0.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.43 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,314.15 | 175 |
| Travel and Lodging | $1,732.81 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $2,327.02 | 21 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $282.92 | 21 | 2025 |
Source payment records
|
|||||
| ONYX FRONTIER Normalized: onyx frontier |
Device | Medtronic, Inc. | $232.04 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $224.05 | 24 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $219.89 | 14 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $218.81 | 17 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $180.54 | 18 | 2025 |
Source payment records
|
|||||
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $164.16 | 8 | 2025 |
Source payment records
|
|||||
| FFRANGIO Normalized: ffrangio |
Device | Medtronic, Inc. | $161.85 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $140.30 | 9 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $98.59 | 4 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $78.96 | 11 | 2025 |
Source payment records
|
|||||
| Optimizer Normalized: optimizer |
Device | Impulse Dynamics (USA) Inc. | $78.29 | 3 | 2025 |
Source payment records
|
|||||
| EMBLEM MRI S-ICD Normalized: emblem mri s icd |
Device | Boston Scientific Corporation | $49.58 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $48.55 | 3 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $47.05 | 2 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $37.33 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $35.54 | 2 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $34.36 | 1 | 2025 |
Source payment records
|
|||||
| MERLIN@HOME Normalized: merlin home |
Device | Abbott Laboratories | $26.10 | 1 | 2025 |
Source payment records
|
|||||
| ENDOCROSS Device Normalized: endocross device |
Device | Endologix LLC | $23.92 | 1 | 2025 |
Source payment records
|
|||||
| Torus Stent Graft System Normalized: torus stent graft system |
Device | Endologix LLC | $23.92 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.87 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $20.14 | 2 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $18.54 | 1 | 2025 |
Source payment records
|
|||||
| KENGREAL Normalized: kengreal |
Drug | Chiesi USA, Inc. | $16.72 | 1 | 2025 |
Source payment records
|
|||||
| IN.PACT ADMIRAL Normalized: in pact admiral |
Device | Medtronic, Inc. | $15.99 | 1 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $15.98 | 1 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $15.96 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.81 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE 6/7F VCS Normalized: cardiva vascade 6 7f vcs |
Device | CARDIVA MEDICAL, INC. | $14.71 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.62 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.43 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $10.20 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $10.20 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 511 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 85 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 78 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 124 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 93 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
23 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
78 | 20 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
124 | 43 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
511 | 162 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
124 | 43 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
85 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
93 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
511 | 162 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 710 | 265 |
| Metoprolol Succinate | Metoprolol Succinate | 672 | 234 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 606 | 208 |
| Clopidogrel | Clopidogrel Bisulfate | 516 | 175 |
| Eliquis | Apixaban | 511 | 162 |
| Amlodipine Besylate | Amlodipine Besylate | 483 | 174 |
| Spironolactone | Spironolactone | 336 | 126 |
| Carvedilol | Carvedilol | 283 | 106 |
| Lisinopril | Lisinopril | 271 | 79 |
| Furosemide | Furosemide | 259 | 92 |
| Ramipril | Ramipril | 259 | 74 |
| Ezetimibe | Ezetimibe | 254 | 102 |
| Valsartan | Valsartan | 244 | 84 |
| Nifedipine Er | Nifedipine | 231 | 81 |
| Xarelto | Rivaroxaban | 229 | 63 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 221 | 82 |
| Losartan Potassium | Losartan Potassium | 214 | 87 |
| Torsemide | Torsemide | 189 | 82 |
| Chlorthalidone | Chlorthalidone | 180 | 73 |
| Alprazolam | Alprazolam | 162 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 140 | 52 |
| Repatha Sureclick | Evolocumab | 138 | 30 |
| Jardiance | Empagliflozin | 124 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 122 | 44 |
| Levothyroxine Sodium | Levothyroxine Sodium | 107 | 42 |
| Simvastatin | Simvastatin | 103 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 94 | 38 |
| Ozempic | Semaglutide | 93 | 30 |
| Entresto | Sacubitril/Valsartan | 85 | 27 |
| Farxiga | Dapagliflozin Propanediol | 78 | 20 |
| Irbesartan | Irbesartan | 74 | 22 |
| Metformin Hcl | Metformin Hcl | 71 | 28 |
| Amiodarone Hcl | Amiodarone Hcl | 67 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 67 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 59 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 54 | 19 |
| Warfarin Sodium | Warfarin Sodium | 49 | 18 |
| Potassium Chloride | Potassium Chloride | 48 | 15 |
| Sotalol | Sotalol Hcl | 47 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 47 | 11 |
| Eplerenone | Eplerenone | 45 | 18 |
| Nebivolol Hcl | Nebivolol Hcl | 45 | 18 |
| Omeprazole | Omeprazole | 45 | 15 |
| Flecainide Acetate | Flecainide Acetate | 44 | 18 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 41 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | 16 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 40 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 39 | 15 |
| Bumetanide | Bumetanide | 38 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | 13 |
| Icosapent Ethyl | Icosapent Ethyl | 35 | 12 |
| Prednisone | Prednisone | 34 | 24 |
| Fenofibrate | Fenofibrate | 30 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Meloxicam | Meloxicam | 30 | 13 |
| Atenolol | Atenolol | 27 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 27 | 12 |
| Diltiazem 24hr Er | Diltiazem Hcl | 27 | 11 |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 26 | suppressed |
| Wegovy | Semaglutide | 26 | suppressed |
| Gabapentin | Gabapentin | 25 | suppressed |
| Multaq | Dronedarone Hcl | 25 | suppressed |
| Metolazone | Metolazone | 24 | 12 |
| Brilinta | Ticagrelor | 23 | 11 |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | 12 |
| Rybelsus | Semaglutide | 22 | suppressed |
| Allopurinol | Allopurinol | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 20 | suppressed |
| Colchicine | Colchicine | 18 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Celecoxib | Celecoxib | 17 | 12 |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Cartia Xt | Diltiazem Hcl | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 13 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Famotidine | Famotidine | 11 | suppressed |
| Livalo | Pitavastatin Calcium | 11 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 11 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 11 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $5,046.96 · 186 records | Medtronic, Inc. | AMVUTTRA, AVEIR, AVVIGO Guidance System, CAMZYOS, CARDIOMEMS, CARDIVA VASCADE 6/7F VCS, ELIQUIS, EMBLEM MRI S-ICD, ENDOCROSS Device, ENTRESTO, FARXIGA, FFRANGIO, FFRct, FUROSCIX, HAWKONE, IN.PACT ADMIRAL, JARDIANCE, KENGREAL, Kerendia, LEQVIO, LifeVest, MERLIN@HOME, NEXLETOL, ONPATTRO, ONYX FRONTIER, Optimizer, Ozempic, REPATHA, Rybelsus, SYMPLICITY G3, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, Torus Stent Graft System, VERQUVO, VYNDAQEL, Wegovy, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error